Susceptibility to daptomycin, quinupristin-dalfopristin and linezolid and some other antibiotics in clinical isolates of methicillin resistant and methicillin sensitive S. aureus from the Oslo area

Scandinavian Journal of Infectious Diseases

Volumn 39, Issue 11-12, 2007, Pages 1059-1062

  Jørgen, Bente ^a   Merckoll, Patricia ^a   Melby, Kjetil K ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; FUSIDATE SODIUM; LINEZOLID; RIFAMPICIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL VIRULENCE; DRUG MONITORING; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; NORWAY; STAPHYLOCOCCUS AUREUS;

EID: 36349006319     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.1080/00365540701466231     Document Type: Article

References (24)

1. Cosgrove, SE and Carmeli, Y. (2003) The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis, 36, pp. 1433-1437.
2. (2005)
3. Cars, O., Molstad, S. and Melander, A. (2001) Variation in antibiotic use in the European Union. Lancet, 357, pp. 1851-1853.
4. Eliopoulos, GM. (2003) Quinupristin-dalfopristin and linezolid: Evidence and opinion. Clin Infect Dis, 36, pp. 473-481.
5. Beyer, D. and Pepper, K. (1998) The streptogramin antibiotics: Updates on their mechanisms of action. Expert Opin Investig Drugs, 7, pp. 591-599.
6. Lina, G., Quaglia, A., Reverdy, ME, Leclercq, R., Vandenesch, F. and Etienne, J. (1999) Distribution of genes encoding resistance to macrolides, lincosamides, and streptogramins among staphylococci. Antimicrob Agents Chemother, 43, pp. 1062-1066.
7. Kehoe, LE, Snidwongse, J., Courvalin, P., Rafferty, JB and Murray, IA. (2003) Structural basis of synercid (quinupristin-dalfopristin) resistance in Gram-positive bacterial pathogens. J Biol Chem, 278, pp. 29963-29970.
8. Leclercq, R., Nantas, L., Soussy, CJ and Duval, J. (1992) Activity of RP 59500, a new parenteral semi-synthetic streptogramin, against staphylococci with various mechanisms of resistance to macrolide-lincosamide-streptogramin antibiotics. J Antimicrob Chemother, 30, pp. 67-75.
9. Shinabarger, DL, Marotti, KR, Murray, RW, Lin, AH, Melchior, EP and Swaney, SM (1997) Mechanism of action of oxazolidinones: Effects of linezolid and eperezolid on translation reactions. Antimicrob Agents Chemother, 41, pp. 2132-2136.
10. Prystowsky, J., Siddiqui, F., Chosay, J., Shinabarger, DL, Millichap, J., Peterson, LR and Noskin, GA. (2001) Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob Agents Chemother, 45, pp. 2154-2156.
11. Tsiodras, S., Gold, HS, Sakoulas, G., Eliopoulos, GM, Wennersten, C. and Venkataraman, L. (2001) Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet, 358, pp. 207-208.
12. Andersen, BM, Dalen, HE, Steinbakk, M., Syversen, G., Bruun, JN and Magnaes, B. (1998) Methicillin resistant yellow staphylococci. Tidsskr Nor Laegeforen, 118, pp. 1182-1185.
13. Brakstad, OG, Maeland, JA and Tveten, Y. (1993) Multiplex polymerase chain reaction for detection of genes for Staphylococcus aureus thermonuclease and methicillin resistance and correlation with oxacillin resistance. APMIS, 101, pp. 681-688.
14. National Committee for Clinical Laboratory Standards (2002) NCCLS, Wayne, PA, USA
15. E-test application sheet-EAS008 AB Biodisk.
16. Henwood, CJ, Livermore, DM, Johnson, AP, James, D., Warner, M. and Gardiner, A. (2000) Susceptibility of Gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group. J Antimicrob Chemother, 46, pp. 931-940.
17. Ballow, CH, Jones, RN and Biedenbach, DJ. (2002) A multicentre evaluation of linezolid antimicrobial activity in North America. Diagn Microbiol Infect Dis, 43, pp. 75-83.
18. Bolmstrom, A., Ballow, CH, Qwarnstrom, A., Biedenbach, DJ and Jones, RN. (2002) Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: Report from the Zyvox antimicrobial potency study (ZAPS-Europe). Clin Microbiol Infect, 8, pp. 791-800.
19. Mutnick, AH, Biedenbach, DJ, Turnidge, JD and Jones, RN. (2002) Spectrum and potency evaluation of a new oxazolidinone, linezolid: Report from the SENTRY Antimicrobial Surveillance Program, 1998-2000. Diagn Microbiol Infect Dis, 43, pp. 65-73.
20. Anastasiou, DM, Thorne, GM, Luperchio, SA and Alder, JD. (2006) In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin. International Journal of Antimicrobial Agents, 28, pp. 385-388.
21. Denis, O., Deplano, A., Nonhoff, C., Hallin, M., De Ryck, R. and Vanhoof, R. (2006) In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin resistant Staphylococcus aureus strains from a national survey of Belgian hospitals. Antimicrobial Agents Chemother, 50, pp. 2680-2685.
22. Sader, HS, Fritsche, TR and Jones, RN. (2005) Antimicrobial activity of daptomycin tested against clinical strains of indicated species isolated in North American medical centres (2003). Diagnostic Microbiology & Infectious Disease, 53, pp. 329-332.
23. Fluit, AC, Schmitz, FJ, Verhoef, J. and Milatovic, D. (2004) Daptomycin in vitro susceptibility in European Gram-positive clinical isolates. International Journal of Antimicrobial Agents, 24, pp. 59-66.
24. Richter, SS, Kealey, DE, Murray, CT, Heilmann, KP, Coffman, SL and Doern, GV. (2003) The in vitro activity of daptomycin against Staphylococcus aureus and Enterococcus species. Journal of Antimicrobial Chemotherapy, 52, pp. 123-127.